Status:
TERMINATED
Inhaled Ciclesonide for Outpatients With COVID19
Lead Sponsor:
McGill University Health Centre/Research Institute of the McGill University Health Centre
Conditions:
COVID 19
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
The CONTAIN (CiclesOnide cliNical TriAl covId-19 treatmeNt) is a randomized control study of ciclesonide vs placebo for mild covid-19 disease. The need for potential therapy for COVID-19 patients is u...
Eligibility Criteria
Inclusion
- Symptomatic adult patients positive by PCR for COVID-19 within 5 days of enrollment with fever, cough, or shortness of breath. Provision of Informed Consent
- At day 0, patients should be at home
Exclusion
- Already on inhaled corticosteroid medication
- Currently using systemic steroids (oral or intravenous or intramuscular such as Prednisone) or use of steroids 7 days prior to enrolment
- Severely ill patients at enrollment (i.e., admitted to ICU at admission)
- Unable to self-administer the inhaler
- Known or suspected pregnancy and breastfeeding
- Known allergy to study medication or its components (non-medicinal ingredients; including lactose allergy (type I))
- Patients with untreated fungal, bacterial, or tubercular infections of the respiratory tract
- Current hospitalization
- Current use of oxygen at home or in the hospital
Key Trial Info
Start Date :
September 15 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 8 2021
Estimated Enrollment :
215 Patients enrolled
Trial Details
Trial ID
NCT04435795
Start Date
September 15 2020
End Date
July 8 2021
Last Update
June 10 2022
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
University of British Columbia
Vancouver, British Columbia, Canada
2
Sunnybrook Hospital
Toronto, Ontario, Canada, M4N 3M5
3
McGill University Health Center
Montreal, Quebec, Canada, H3K 2M2